Moleculin Biotech (MBRX)

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 20 Jun 2018 15:21

Approved!!!!! Hier zat ik op te wachten!

Moleculin Receives Approval for Leukemia Clinical Trial

June 20, 2018 07:30 ET | Source: Moleculin Biotech, Inc.
HOUSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has received Polish National Office approval to begin its second Phase I/II clinical trial to study Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (“AML”).

“This approval is a significant step forward to be able to treat additional patients with AML and to generate positive clinical data regarding Annamycin,” commented Walter Klemp, Chairman and CEO of Moleculin. “Consent from the Polish National Office was the final step required to allow us to begin recruiting patients for this important trial. Enrollment will begin immediately and we expect patients to commence receiving treatment, at the appropriate dose, in this clinical trial during the second half of this year.”
alles kan beter liked last!



Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 965
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 371
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor alles kan beter » 20 Jun 2018 16:59

Moleculin Biotech : up 8.2 pct
BUZZ-Rises on approval to start cancer drug trial
Just when you think you've hit rock bottom, someone will hand you a shovel.

Gebruikersavatar
neku
Premiummember
Premiummember
Berichten: 1518
Lid geworden op: 01 Jan 2017 20:21
Locatie: Antwerpen
waarderingen: 378
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor neku » 20 Jun 2018 17:36

alles kan beter schreef:Moleculin Biotech : up 8.2 pct
BUZZ-Rises on approval to start cancer drug trial


al 15,47% omhoog, instapje gedaan daarstraks :D
The aim of education is the knowledge, not of facts, but of values!

Gebruikersavatar
alles kan beter
Premiummember
Premiummember
Berichten: 965
Lid geworden op: 03 Aug 2017 08:03
Locatie: +9000
waarderingen: 371
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor alles kan beter » 20 Jun 2018 18:40

blijft even hangen maar nog altijd vermelding in de buzz stocks on the move

:D
Just when you think you've hit rock bottom, someone will hand you a shovel.

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor Munnybunny » 21 Jun 2018 13:38

Moleculin Announces $2.3 Million Registered Direct Offering Priced At-the-market


June 21, 2018 07:30 ET | Source: Moleculin Biotech, Inc.
HOUSTON, June 21, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that it has entered into a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $2.3 million. The closing of the offering is expected to take place on or about June 22, 2018, subject to the satisfaction of customary closing conditions.

In connection with the offering, the Company will issue 1,092,636 registered shares of common stock at a purchase price of $2.105 per share. Concurrently in a private placement, for each share of common stock purchased by an investor, such investor will receive from the Company an unregistered warrant to purchase 0.65 of a share of common stock. The warrants have an exercise price of $2.02 per share, will be exercisable six months from the date of issuance, and will expire five years from the initial exercise date.

Roth Capital Partners served as sole placement agent for the offering.

The Company intends to use the net proceeds of this offering for its planned clinical trials, preclinical programs, for other research and development activities and for general corporate purposes.

The shares of common stock described above (but not the warrants or the shares of common stock underlying the warrants) are being offered pursuant to a shelf registration statement (File No. 333-219434) which became effective on August 21, 2017. Such shares of common stock may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement.

Gebruikersavatar
neku
Premiummember
Premiummember
Berichten: 1518
Lid geworden op: 01 Jan 2017 20:21
Locatie: Antwerpen
waarderingen: 378
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor neku » 29 Jun 2018 20:59

Deze week kreeg MBRX wel een pandoering maar doet er vandaag toch al 5% terug bij :up:
The aim of education is the knowledge, not of facts, but of values!

Gebruikersavatar
neku
Premiummember
Premiummember
Berichten: 1518
Lid geworden op: 01 Jan 2017 20:21
Locatie: Antwerpen
waarderingen: 378
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor neku » 06 Jul 2018 23:17

Beetje "oud" nieuws maar soit ;)

Press Release: Moleculin Selected for the Russell Microcap Index

Moleculin Selected for the Russell Microcap Index

HOUSTON, June 26, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced the Company was selected to be added to the Russell Microcap(R) Index effective after the U.S. market opened on June 25, 2018, when the Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes.

"We are pleased that Moleculin was selected to be included in the Russell Microcap Index," commented Walter Klemp, Chairman and CEO of Moleculin. "We believe our addition to this index will increase our visibility within the investment community and potentially help to enhance shareholder value."

Membership in the Russell Microcap(R) Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell US Indexes primarily by objective, market-capitalization rankings and style attributes.

For more information on the Russell Microcap(R) Index and the Russell US Indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.

For more information about the Company, please visit http://www.moleculin.com.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the actions of FTSE Russell as it relates to the addition of Moleculin to the Russell Microcap Index. These statements relate to future events, future expectations, plans and prospects. Although Moleculin Biotech believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may, " "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Contacts
Joe Dorame, Robert Blum or Joe Diaz
Lytham Partners, LLC
602-889-9700
mbrx@lythampartners.com
(END) Dow Jones Newswires
June 26, 2018 07:30 ET (11:30 GMT)
The aim of education is the knowledge, not of facts, but of values!

Gebruikersavatar
neku
Premiummember
Premiummember
Berichten: 1518
Lid geworden op: 01 Jan 2017 20:21
Locatie: Antwerpen
waarderingen: 378
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor neku » 06 Jul 2018 23:21

Technische Analyse :!:

Hervatting van de vijandelijkheden!

De recente zeer steile neerwaartse druk zou moeten blijven aanhouden en er is geen enkele aanwijzing van omkering. De verkopers hebben de touwtjes in handen. Het sentiment rond MBRX is eerder neutraal (het aandeel is niet overkocht noch oververkocht) maar er is momenteel een verslechtering van het klimaat. Statistisch gezien (in functie van de vorige volatiliteitsmaatregelen) tekent er zich een technische verslechtering af aan de horizon.

Men zal op de volgende koersdoelen inspelen:

Volgende technische steun op 1,65 $ (bodem van 2018-06-28), dat -2,94% dalingspotentieel laat. Verder wordt een belangrijke steun verwacht in het gebied van 1,58 $ (-7,06% lager).

Scenario Invalidatie

Zodra uitbraak boven de weerstand op Verder wordt een belangrijke weerstand verwacht op 2,43 $ (42,94% boven de huidige koersen).
The aim of education is the knowledge, not of facts, but of values!

Gebruikersavatar
neku
Premiummember
Premiummember
Berichten: 1518
Lid geworden op: 01 Jan 2017 20:21
Locatie: Antwerpen
waarderingen: 378
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor neku » 12 Jul 2018 19:24

+5% erbij vandaag :clap:
The aim of education is the knowledge, not of facts, but of values!

Gebruikersavatar
neku
Premiummember
Premiummember
Berichten: 1518
Lid geworden op: 01 Jan 2017 20:21
Locatie: Antwerpen
waarderingen: 378
Contact:

Re: Moleculin Biotech (MBRX)

Berichtdoor neku » 12 Jul 2018 22:06

neku schreef:+5% erbij vandaag :clap:

gezakt naar +1,78 :think:
The aim of education is the knowledge, not of facts, but of values!